CRP and rheumatoid arthritis: In patients with RA and RF levels >204 IU/ml, the proportion of patients achieving DAS28-CRP LDA and DAS28-ESR LDA at week 104 were 36% and 38% higher in CZP-treated patients relative to ADA-treated patients, respectively; there was little difference between CZP- and ADA-treated patients with RF levels ≤204 IU/ml.